QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
NASDAQ:BLUE

bluebird bio Stock Forecast, Price & News

$6.93
-0.62 (-8.21%)
(As of 01/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.91
$7.66
50-Day Range
$6.93
$11.68
52-Week Range
$6.91
$48.92
Volume
5.53 million shs
Average Volume
1.87 million shs
Market Capitalization
$485.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.55
30 days | 90 days | 365 days | Advanced Chart
Receive BLUE News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.


bluebird bio logo

About bluebird bio

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Headlines

bluebird bio (NASDAQ:BLUE) Sees Large Volume Increase
January 20, 2022 |  americanbankingnews.com
bluebird bio (NASDAQ:BLUE) Reaches New 12-Month Low at $8.12
January 18, 2022 |  americanbankingnews.com
Why Bluebird Bio Stock Is Sinking This Week
January 14, 2022 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLUE
Fax
N/A
Employees
1,213
Year Founded
N/A

Sales & Book Value

Annual Sales
$250.73 million
Book Value
$20.42 per share

Profitability

Net Income
$-618.70 million
Net Margins
-1,610.78%
Pretax Margin
-1,609.99%

Debt

Price-To-Earnings

Miscellaneous

Free Float
68,074,000
Market Cap
$485.84 million
Optionable
Optionable

Company Calendar

Last Earnings
11/05/2021
Today
1/20/2022
Next Earnings (Estimated)
2/22/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.55 out of 5 stars

Medical Sector

108th out of 1,418 stocks

Biological Products, Except Diagnostic Industry

14th out of 206 stocks

Analyst Opinion: 4.1Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -












bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

Is bluebird bio a buy right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 1 sell rating, 13 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" bluebird bio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View analyst ratings for bluebird bio
or view top-rated stocks.

How has bluebird bio's stock price been impacted by COVID-19 (Coronavirus)?

bluebird bio's stock was trading at $61.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BLUE stock has decreased by 88.7% and is now trading at $6.93.
View which stocks have been most impacted by COVID-19
.

When is bluebird bio's next earnings date?

bluebird bio is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for bluebird bio
.

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) released its earnings results on Friday, November, 5th. The biotechnology company reported ($3.16) earnings per share for the quarter, missing the Zacks' consensus estimate of ($2.65) by $0.51. The biotechnology company had revenue of $22.70 million for the quarter, compared to the consensus estimate of $39.07 million. bluebird bio had a negative trailing twelve-month return on equity of 76.93% and a negative net margin of 1,610.78%. The firm's revenue was up 17.6% on a year-over-year basis. During the same period in the prior year, the business earned ($2.94) earnings per share.
View bluebird bio's earnings history
.

What price target have analysts set for BLUE?

17 analysts have issued twelve-month price objectives for bluebird bio's stock. Their forecasts range from $10.00 to $39.00. On average, they anticipate bluebird bio's share price to reach $18.21 in the next year. This suggests a possible upside of 162.8% from the stock's current price.
View analysts' price targets for bluebird bio
or view top-rated stocks among Wall Street analysts.

Who are bluebird bio's key executives?

bluebird bio's management team includes the following people:

What is Nick Leschly's approval rating as bluebird bio's CEO?

66 employees have rated bluebird bio CEO Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among bluebird bio's employees.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), (CELG), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Cutler Group LP (0.00%). Company insiders that own bluebird bio stock include Alison Cecily Finger, Andrew Obenshain, David Davidson, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly and William D Baird III.
View institutional ownership trends for bluebird bio
.

Which major investors are selling bluebird bio stock?

BLUE stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP. Company insiders that have sold bluebird bio company stock in the last year include Andrew Obenshain, Jason Cole, Jessica Whitten, Katy Burnett, Nick Leschly, and William D Baird III.
View insider buying and selling activity for bluebird bio
or view top insider-selling stocks.

How do I buy shares of bluebird bio?

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $6.93.

How much money does bluebird bio make?

bluebird bio has a market capitalization of $485.84 million and generates $250.73 million in revenue each year. The biotechnology company earns $-618.70 million in net income (profit) each year or ($12.82) on an earnings per share basis.

How many employees does bluebird bio have?

bluebird bio employs 1,213 workers across the globe.

What is bluebird bio's official website?

The official website for bluebird bio is www.bluebirdbio.com.

Where are bluebird bio's headquarters?

bluebird bio is headquartered at 60 BINNEY STREET, CAMBRIDGE MA, 02142.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at (339) 499-9300 or via email at [email protected].


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.